Zacks Investment Research downgraded shares of BLUEBIRD BIO (BLUE) from NEUTRAL to UNDERPERFORM on March 10, 2014, with a target price of $24.70.
Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on BLUEBIRD BIO (BLUE),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment